Literature DB >> 16239389

Update on rituximab.

R Eisenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16239389      PMCID： PMC1766904          DOI： 10.1136/ard.2005.042648

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  25 in total

1.  Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.

Authors:  Nancy L Monson; Petra D Cravens; Elliot M Frohman; Kathleen Hawker; Michael K Racke
Journal:  Arch Neurol       Date:  2005-02

Review 2.  CD20: a regulator of cell-cycle progression of B lymphocytes.

Authors:  T F Tedder; P Engel
Journal:  Immunol Today       Date:  1994-09

Review 3.  Treatment of SLE with anti-CD20 monoclonal antibody.

Authors:  R John Looney; Jennifer Anolik; Iñaki Sanz
Journal:  Curr Dir Autoimmun       Date:  2005

4.  Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.

Authors:  Jennifer H Anolik; Jennifer Barnard; Amedeo Cappione; Aimee E Pugh-Bernard; Raymond E Felgar; R John Looney; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-11

5.  Rituximab in the treatment of dermatomyositis: an open-label pilot study.

Authors:  Todd D Levine
Journal:  Arthritis Rheum       Date:  2005-02

6.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2005-01

Review 7.  TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.

Authors:  J Keane
Journal:  Rheumatology (Oxford)       Date:  2005-03-01       Impact factor: 7.580

8.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

9.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Authors:  P McLaughlin; A J Grillo-López; B K Link; R Levy; M S Czuczman; M E Williams; M R Heyman; I Bence-Bruckler; C A White; F Cabanillas; V Jain; A D Ho; J Lister; K Wey; D Shen; B K Dallaire
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

10.  Mice carrying a CD20 gene disruption.

Authors:  T L O'Keefe; G T Williams; S L Davies; M S Neuberger
Journal:  Immunogenetics       Date:  1998-07       Impact factor: 2.846
View more
  13 in total

Review 1.  Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.

Authors:  Jeremy M Clain; Rodrigo Cartin-Ceba; Fernando C Fervenza; Ulrich Specks
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

2.  Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.

Authors:  L Bartalena; M L Tanda
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 3.  Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases.

Authors:  C Hu; F S Wong; L Wen
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

4.  B-cell-targeted therapy for systemic lupus erythematosus.

Authors:  Ramin Sabahi; Jennifer H Anolik
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice.

Authors:  Ikuko Hayakawa; Thomas F Tedder; Yuan Zhuang
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

Review 6.  The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs).

Authors:  Gerwyn Morris; Michael Berk; Piotr Galecki; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-09-26       Impact factor: 5.590

7.  Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Therese Vallerskog; Mikael Heimbürger; Iva Gunnarsson; Wei Zhou; Marie Wahren-Herlenius; Christina Trollmo; Vivianne Malmström
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

8.  Rapidly fatal Acanthamoeba encephalitis and treatment of cryoglobulinemia.

Authors:  Wouter Meersseman; Katrien Lagrou; Raf Sciot; Johan de Jonckheere; Christine Haberler; Julia Walochnik; Willy E Peetermans; Eric van Wijngaerden
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

Review 9.  Recent advances in the field of anti-cancer immunotherapy.

Authors:  Henrique Neves; Hang Fai Kwok
Journal:  BBA Clin       Date:  2015-04-18

Review 10.  Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics.

Authors:  Gerwyn Morris; Michael Maes
Journal:  BMC Med       Date:  2013-09-17       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.